Data from the NCSI Study Demonstrates 72% Survival with 98% Native Heart Recovery

Data from the National Cardiogenic Shock Initiative (NCSI) study on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% native heart recovery at discharge. The patients were treated with the NCSI study protocol, which includes placing the Impella® heart pump before revascularization. The study demonstrates the protocol-based approach to increasing survival rates in cardiogenic shock is reproducible in academic and community hospitals across the United States. Results were presented at the 2019 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions and simultaneously published in Catheterization and Cardiovascular Interventions (CCI).

The investigators of the physician-led NCSI study represent the largest working group studying the effects of mechanical circulatory support in AMICS patients. Their goals are to increase cardiogenic shock survival, which has stagnated for the last 20 years at around 50% and provide unloading therapy to achieve native heart recovery. The NCSI study protocol includes best practices of placing Impella pre-PCI, identifying shock early and minimizing the use of inotropes. These best practices were identified retrospectively through Abiomed’s Impella Quality (IQ) Database and the U.S. Impella Registry, now called the cVAD Study, and were tested and validated prospectively in the original Detroit CSI study, which demonstrated improved survival and native heart recovery.